Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.

Authors:
Laneuville P; Barnett MJ; Bélanger R; Couban S; Forrest DL and 2 more

Journal:
Curr Oncol

Publication Year: 2006

PMCID:
PMC3394607

PMID:
22792021

View on PubMed View on PMC
Journal Information

Full Title: Curr Oncol

Abbreviation: Curr Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioper…
Radros J; Kjellman A; Henningsohn L and 7 more (2024) - Transparency Score: 3/6
Acute Diabetes-Related Complications in Patients Receiving Chemoradiotherapy for Head and Neck Canc…
Mellor R; Girgis CM; Rodrigues A and 7 more (2024) - Transparency Score: 3/6
Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer.
Conces ML; Mahipal A. (2024) - Transparency Score: 3/6
A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.
Moria FA; Park CL; Eigl BJ and 3 more (2024) - Transparency Score: 3/6
Artemis as Predictive Biomarker of Responsiveness to Preoperative Chemoradiotherapy in Patients wit…
Liu H; Huang R; Shan J and 4 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"4. DISCLOSURE The following physicians disclosed that they have received honoraria from Novartis Pharmaceuticals Canada Inc. for consultancy: Pierre Laneuville, Jeffrey H. Lipton, Michael Barnett, Robert Belanger, Stephen Couban, Donna Forrest, Denis-Claude Roy. Dr. Lipton also disclosed that he has received honoraria from Novartis Pharmaceuticals Canada Inc. as a participant in a speaker’s bureau."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025